Article information
Full text is only aviable in PDF
REFERENCES
[1]
MM McNeil, SL Nash, RA Haijeh, RA Majjeh, MA Phelan, LA Conn, et al.
Trends in mortality due to invasive mycotic diseases in the United States 1980–1987.
Clin Infect Dis, 33 (2001), pp. 641-647
[2]
L Kaiser, T Huguenin, PO Lew, R Chapis, D Pilter.
Invasive aspergillosis. Clinical features of 35 proven cases at a single institution.
Medicine (Baltimore), 77 (1998), pp. 188-194
[3]
AH Groll, PM Shah, C Mentzel, M Schneider, G Just-Nuebling, et al.
Trends in the post mortem epidemiology of invasive fungal infections at a university hospital.
J Infect, 33 (1996), pp. 23-32
[4]
O Lortholary, S Ascioglu, P Moreau, R Herbrecht, A Marimis, P Casassus, et al.
Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma. A European Organization for Research and Treatment of Cancer/Invasive Fungal Infections. Cooperative Group and the Intergroupe Français du Myélome.
Clin Infect Dis, 30 (2000), pp. 41-46
[5]
SJ Lin, S Schranz, SM Theutsch.
Aspergillosis case-fatality rate: systematic review of the literature.
Clin Infect Dis, 32 (2001), pp. 358-366
[6]
KA Marr, RA Bowden.
Fungal infections in patients undergoing blood and marrow transplantation.
Transpl Infect Dis, 1 (1999), pp. 237-246
[7]
JL Vincent, DJ Bihari.
The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIIC) Study.
JAMA, 274 (1995), pp. 639-644
[8]
F Álvarez Lerma, E Cerda, R Jordá, M Palomar, M Bermejo.
Fungal isolates in critically ill patients admitted to intensive care units.
Intensive Care Med, 26 (2000), pp. 234
[9]
MA Sánchez, C León, J Nolla, R Jordá, MA León, MJ Pontes, Study Group EPCAN.
Use of antifungal agents in critically ill patients. A Spanish multicentre study. Final results.
Intensive Care Med, 26 (2000), pp. 376
[10]
The genus Aspergillus,
[11]
MF VandenBergh, PE Verweij, A Voss.
Epidemiology of nosocomial fungal infections: invasive aspegillosis.
Diagn Microbiol Infect Dis, 34 (1999), pp. 221-227
[12]
AO Soubani, PH Chandrasekar.
The clinical spectrum of pulmonary aspergillosis.
Chest, 121 (2002), pp. 1988-1999
[13]
PE Verweij, BE De Pauw.
Avances recientes en el manejo de la aspergilosis nosocomial en unidades onco-hematológicas.
Infección, pp. 157-176
[14]
P Ussetti, A De Pablo, M Cruz.
Aspergilosis pulmonar.
Implicaciones terapéuticas de la neumonía nosocomial grave, pp. 97-108
[15]
CJ Clancy, MH Nguyen.
Acute community-acquired pneumonia due to Aspergillus in presumably immunocompetent hosts.
Chest, 114 (1998), pp. 629-634
[16]
HJ Schwartz, PA Greenberger.
The prevalence of allergic bronchopulmonary aspergillosis in patients with asthma, determined by serologic and radiologic criteria in patients at risk.
J Lab Clin Med, 117 (1991), pp. 138-142
[17]
G Mastella, M Rainisio, HK Harms, ME Hodson, C Koch, J Navarro, et al.
Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study.
Eur Respir J, 16 (2000), pp. 464-471
[18]
OP Sharma, R Chwogule.
Many faces of pulmonary aspergillosis.
Eur Respir J, 12 (1998), pp. 705-715
[19]
R Patterson, PA Greenberger, RC Radin, M Roberts.
Allergic bronchopulmonary aspergillosis: staging as an aid to management.
Ann Intern Med, 198 (1998), pp. 286-291
[20]
M Rosenberg, R Patterson, R Mintzer, et al.
Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis.
Ann Intern Med, 86 (1977), pp. 405-414
[21]
PA Greenberger, R Patterson.
Diagnosis and management of allergic bronchopulmonary aspergillosis.
Ann Allergy, 56 (1986), pp. 444-452
[22]
Greenberger PA, Miller TP, Roberts M, Smith LL. Allergic bronchopulmonary aspergillosis in patients with and without bronchiectasis. Ann Allergy 1993;70:21-3. Proceedings of the Cystic Fibrosis Foundation ABPA Consensus Conference; 2001, June 12–13; Bethesda, Md.
[24]
M Rosenberg, R Patterson, M Roberts, J Wang.
The assessment of immunologic and clinical changes occurring during corticosteroid therapy for allergic bronchopulmonary aspergillosis.
Am J Med, 64 (1978), pp. 599-605
[25]
BH Safirstein, MF D'Souza, G Simon, EHC Tai, J Pepys.
Five-year follow-up of allergic bronchopulmonary aspergillosis.
Am Rev Respir Dis, 108 (1973), pp. 450-459
[26]
J Wang, R Patterson, M Roberts.
The management of allergic bronchopulmonary aspergillosis.
Am Rev Respir Dis, 120 (1979), pp. 87-92
[27]
WG Middleton, IC Paterson, IWB Grant, AC Douglas.
Asthmatic pulmonary eosinophilia: a review of 65 cases.
Br J Dis Chest, 71 (1977), pp. 115-122
[28]
British Thoracic Association.
Inhaled beclomethasone dipropionate in allergic bronchopulmonary aspergillosis: report to the Research Committee of the British Thoracic Association.
Br J Dis Chest, 73 (1979), pp. 349-356
[29]
DC Carrie, C Lueck, HB Milburn.
Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis.
Thorax, 45 (1990), pp. 447-450
[30]
GK Crompton, LIR Milne.
Treatment of bronchopulmonary aspergillosis with clotrimazole.
Br J Dis Chest, 67 (1973), pp. 301-307
[31]
DJ Shale, JA Faux, DJ Lane.
Trial of ketoconazole in non-invasive pulmonary aspergillosis.
Thorax, 42 (1987), pp. 26-31
[32]
DA Stevens, HJ Schwartz, JY Lee, BL Moskovitz, DC Jerome, A Catanzano, et al.
A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis.
N Engl J Med, 342 (2000), pp. 756-762
[34]
DN Denning, DA Stevens.
Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases.
Rev Infect Dis, 12 (1990), pp. 1147-1201
[35]
MA Martínez López, JM Peña, J Quiralte, MC Fernández, JJ González, M Patrón.
Bronchocentric granulomatosis associated with pure red cell aplasia and lymphadenopathy.
Thorax, 47 (1992), pp. 131-133
[36]
F Reichemberger, JM Habicht, A Gratwohl, M Tamm.
Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients.
Eur Respir J, 19 (2002), pp. 743-755
[37]
TF Patterson, WR Kirkpatrick, M White, JW Hiemenz, JR Wingard, B Dupont, et al.
Invasive aspergillosis: disease spectrum, treatment practices, and outcomes: 13 Aspergillus Study Group.
Medicine (Baltimore), 79 (2000), pp. 250-260
[38]
J Rello, ME Esandi, D Mariscal, M Gallego, C Domingo, J Vallés.
Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review.
Clin Infect Dis, 26 (1998), pp. 1473-1475
[39]
PA Bulpa, AM Dive, MG Garrino, MA Delos, MR González, PA Evrard, et al.
Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care?.
Intensive Care Med, 27 (2001), pp. 59-67
[40]
B Mehrad, G Paciocco, FJ Martínez, TC Ojo, MD Iannettoni, Lynch JP III.
Spectrum of Aspergillus infection in lung transplant recipients. Case series and review of the literature.
Chest, 119 (2001), pp. 169-175
[41]
E Mylonakis, TF Barlam, T Flanigan, JD Rich.
Pulmonary aspergillosis and invasive disease in AIDS. Review of 342 cases.
Chest, 114 (1998), pp. 251-262
[42]
JR Perfect, GM Cox, JY Lee, CA Kauffman, L De Repentigny, SW Chapman, et al.
The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis.
Clin Infect Dis, 33 (2001), pp. 1824-1833
[43]
DA Stevens, VL Kan, MA Judson, VA Morrison, S Dummer, DW Denning, et al.
Practice guidelines for diseases caused by Aspergillus. Infection Diseases Society of America.
Clin Infect Dis, 30 (2000), pp. 696-709
[44]
MJ Brown, SA Warthy, JD Flint.
Invasive aspergillosis in the immunocompromised host: utility of computed tomography and bronchoalveolar lavage.
Clin Radiol, 53 (1998), pp. 255-257
[45]
T Franquet, NL Muller, A Giménez, P Guembe, J De la Torre, S Bague.
Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings.
Radiographics, 21 (2001), pp. 825-837
[46]
M Kami, T Fukui, S Ogawa.
Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis.
Clin Infect Dis, 33 (2001), pp. 1504-1512
[47]
J Maertens, J Verhaegen, K Lagrou.
Screening for circulating galactomannan as a noninvasive diagnosis tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.
Blood, 97 (2001), pp. 1604-1610
[48]
L Turín, F Riva, G Galbiati, T Cainelli.
Fast, simple and highly sensitive double rounded polymerase chain reaction assay to detect medically relevant fungi in dermatological specimens.
Eur J Clin Invest, 30 (2000), pp. 511-518
[49]
H Hebart, J Loffler, C Meisner.
Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening.
J Infect Dis, 181 (2000), pp. 1713-1719
[50]
J Loffler, H Hebart, U Brauchle, U Schumacher, H Einsele.
Comparison between plasma and whole blood specimens for detection of Aspergillus DNA by PCR.
J Clin Microbiol, 38 (2000), pp. 3830-3833
[51]
TJ Walsh, JW Hiemenz, NL Seibel, JR Perfect, G Harwith, L Lee, et al.
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
Clin Infect Dis, 26 (1998), pp. 1383-1396
[52]
J Tollemar, L Klingspor, O Ringlen.
Liposomal amphotericin B (AmBisome) for fungal infection in immunocompromised adults and children.
Clin Microbiol Infect, 7 (2001), pp. 68-79
[53]
DW Denning, JY Lee, JS Hostetler, P Pappas, CA Kauffman, DH Dewsnup, et al.
Mycosis Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis.
Am J Med, 7 (1994), pp. 135-144
[54]
DA Stevens, JY Lee.
Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria.
Arch Intern Med, 157 (1997), pp. 1857-1862
[55]
D Caillot, H Bassaris, A McGeer, C Arthur, HG Prentice, W Seifert, et al.
Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.
Clin Infect Dis, 33 (2001), pp. E83-E90
[56]
CA Thompson.
New type of antifungal approved for invasive aspergillosis.
Am J Health Syst Pharm, 58 (2001), pp. 558
[57]
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JUV, et al. Open randomized comparison of voriconazole and amphotericin B followed by other licensed antifungal therapy for primary therapy of invasive aspergillosis. American Society for Microbiology, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago IL, USA, 2001; p. 378.
[58]
R Herbrecht, DW Denning, FT Patterson, JE Bennet, for the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group.
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
N Engl J Med, 347 (2002), pp. 408-415
[59]
CH Pun, JM Boyett, WT Hughes, WM Crist.
A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor after remission induction chemotherapy in children with acute lymphocytic leukemia.
N Engl J Med, 336 (1997), pp. 1781-1787
[60]
J Nemunaitis.
Use of macrophage colony-stimulating factor in the treatment of fungal infections.
Clin Infect Dis, 26 (1998), pp. 1279-1281
[61]
JM Rowe.
Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections.
Clin Infect Dis, 26 (1998), pp. 1290-1294
[62]
Y Kanda, R Yamamoto, A Chizuka, T Hamaki, H Suguro, C Arai, et al.
Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.
Cancer, 89 (2000), pp. 1611-1625
[63]
S Schwartz, G Behre, V Heinemann, K Lenz, WD Ludwig, H Wandt, et al.
Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial.
Blood, 93 (1999), pp. 3654-3661
[64]
N Singh.
Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy.
Clin Infect Dis, 31 (2000), pp. 545-553
[65]
JE Patterson, J Peters, JH Calhoon, S Levine, A Anzueto, H Al-Abdely, et al.
Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients.
Transpl Infect Dis, 2 (2000), pp. 22-28
[66]
RP Baughman.
The lung in the immunocompromised patient. Infectious complications part 1.
Respiration, 66 (1999), pp. 95-100
[68]
T Birsan, S Taghavi, W Klepetko.
Treatment of aspergillus-related ulcerative tracheobronchitis in lung transplant recipients.
J Heart Lung Transplant, 17 (1998), pp. 437-438
[69]
J Hamacher, A Apilioponlos, AM Kurt.
Pre-emptive therapy with azoles in lung transplant patients.
Eur Respir J, 13 (1999), pp. 180-186
[70]
T Kato, U Ikuji, M Hiroki, G Mashiro, H Masayoshi, N Atsushi, et al.
Chronic necrotizing pulmonary aspergillosis in pneumoconiosis. Clinical and radiologic findings in 10 patients.
Chest, 121 (2002), pp. 118-127
[71]
T Franquet, NL Muller, A Giménez, P Domingo, V Plaza, R Bordes.
Semiinvasive pulmonary aspergillosis in chronic obstructive pulmonary disease: radiologic and pathologic findings in nine patients.
AJR Am J Roentgenol, 174 (2000), pp. 51-56
[72]
DW Denning.
Chronic forms of pulmonary aspergillosis.
Clin Microbiol Infect, 7 (2001), pp. 25-31
[73]
MW Pound, RH Drew, JR Perfect.
Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia.
Curr Opin Infect Dis, 15 (2002), pp. 183-194
[74]
S Kawamura, S Maesaki, K Tomono, T Tashiro, S Kohno.
Clinical evaluation of 61 patients with pulmonary aspergilloma.
Intern Med, 39 (2000), pp. 209-212
[75]
British Tuberculosis and Thoracic Association.
Aspergilloma and residual tuberculous cavities: the results of a resurvey.
Tubercle, 41 (1970), pp. 227-245
[76]
H Yamada, S Kono, H Koga.
Topical treatment of pulmonary aspergilloma and antifungals: relationship between duration of the disease and efficacy of therapy.
Chest, 103 (1993), pp. 1421-1425
[77]
PL Munk, AD Vellet, RN Rankin, NL Muller, D Ahmad.
Intracavitary aspergilloma: transthoracic percutaneous injection of amphotericin gelatin solution.
Radiology, 188 (1993), pp. 821-823
[78]
M Rumbak, G Kohler, C Eastrige, H Winer-Muram, M Gravant.
Topical treatment of life-threatening hemoptysis from aspergilloma.
Thorax, 51 (1996), pp. 253-255
[79]
G Massard, N Roeslin, JM Wihlm, P Dumont, JP Witz, G Morand.
Pleuropulmonary aspergilloma: clinical spectrum and result of surgical treatment.
Ann Thorax Surg, 54 (1992), pp. 1159-1164
Copyright © 2004. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
